The Oncology CRO
for Biotech, Powered
by Technology
Delivering faster, better, cheaper oncology trial results for biotech sponsors
Our Oncology CRO Executive Team
Our Oncology CRO team has extensive experience leading CROs across indications
Our experienced CRO executive team works closely with our expert site operations team to continuously review execution strategies, closely monitor patient recruitment efforts, and mitigate key study risks for oncology clinical trials.
Richard McCormick Jr.
EVP of Clinical Strategy
Prominent leader, clinical operations and project management professional with 20+ years of experience specializing in hematology and oncology indications to support complex oncology research for biotech clients.
Powered By Our Connected Technology Platform
The Vial Technology Platform leverages connected systems and intuitive design to run global trials efficiently at scale
Vial’s modern technology platform brings clinical trials out of the paper stone age, allowing for streamlined processes inside one end-to-end system.
NGS Integrations
Integrations with leading NGS providers and multi-omics vendors to support targeted oncology sponsors.
No-Nonsense Pricing
Vial offers sponsors fixed-pricing
agreements with no change orders — ever.
Flat-rate pricing
Zero change orders
Risk-share
on commitments
Accountability
on commitments
A fixed-fee pricing model guarantees a set budget for the entirety of a project, regardless of the time and expense that accrues. Vial reserves the right to modify pricing in accordance with amendments to the study design or protocol.
Vial offers fixed upfront pricing to benefit sponsors:
- Align Incentives
- Transparent budget visibility
- No unexpected charges/fees
- Shared accountability on commitments
- Build trust and deepen the relationship
- Experienced team committed to timelines
- Next-generation technology to streamline workflows and process
- A renowned scientific advisory board providing expert insight
- Deep industry relationships and a preferred site network provide an insider view on trial pain points, allowing us to target and prepare to prevent common errors or delays
Modern Recruiting Platform
We recruit patients across multiple channels and convert them to randomizations — radically reducing enrollment periods
We use the most effective digital tools to reach, screen, and enroll motivated subjects quicker. Our optimized process can cut recruitment times in half.
EMR Integrations
HIPAA compliant automated data pulls and Inclusion/Exclusion reviews.
Fast Start-up and Consolidated Site Activation
Vial’s Site Startup App enables sites to seamlessly onboard to our trials
The results: Lightning fast onboarding for sites to be activated in as few as 30 days.
Scientific Advisory Board
Vial CRO is supported by a team of Scientific Advisors who review and provide input on the strategy and direction of the CRO in order to build the infrastructure to advance Oncology research.
Medical Director for Lean and Quality Improvement, Chair of the Lymphoma/Myeloma Disease Working Group, and Associate Professor at the University of Kansas
Professor of Medicine and the Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute
Clinical Executive Director at AccessHope, thoracic oncology specialist and Associate Clinical Professor in Medical Oncology at City of Hope Cancer Center
Genitourinary Medical Oncology Professor and Physician, The University of Texas MD Anderson Cancer Center
Experience across
Immuno-Oncology
The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of monoclonal antibodies.
Dr. Neeraj Agarwal
Professor of Medicine and Presidential Endowed Chair of Cancer Research
at the Huntsman Cancer Institute, University of Utah
Dr. Guru Sonpavde
Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School
The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of cell therapies.
Dr. Arati Rao
Head of Clinical Development at PACT Pharma
The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of checkpoint inhibitors.
Dr. Antoni Ribas
Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA)
Dr. Guru Sonpavde
Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School
Dr. Nathan Pennell
Professor of Medicine and the Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute
Dr. Brian Rini
Chief of Clinical Trials and Professor of Medicine at Vanderbilt University
The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of cancer vaccines.
Dr. Guru Sonpavde
Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School
Dr. Eric Jonasch
Genitourinary Medical Oncology Professor and Physician at The University of Texas MD Anderson Cancer Center
Past Events
Tech-Enabled Remote Monitoring Part 1
Download the Vial CRO's white paper to learn more about each stakeholder’s benefits of tech-enabled trials.
Tech-Enabled Remote Monitoring Part 2
Download the Vial CRO's white paper to learn more about each stakeholder’s benefits of tech-enabled trials.
Vial’s Deployment of Modern, Intuitive Electronic Source
Download the Vial CRO's latest white paper to learn how utilizing eSource in clinical trials can streamline process, increase efficiency, and minimize...
Advancing Cancer Care
Despite significant progress in cancer research, many patients still face limited treatment options.
Clinical trials are essential for developing new cancer treatments and advancing care for patients. Vial offers oncology sponsors solutions to support their research, including optimized study design, innovative patient recruitment strategies, and advanced data analytics techniques. By leveraging Vial, sponsors conducting oncology clinical trials can accelerate getting innovative therapies to the market, leading to better patient outcomes and contributing to the global effort to cure cancer.
Indications
Multifaceted Clinical Trial Execution Across Oncology Indications and Phases
- Acute myeloid leukemia (AML)
- Bone marrow transplant
- Breast cancer
- Carcinoma in situ (CIS) bladder cancer
- Cervical cancer
- Chronic lymphocytic leukemia (CLL)
- Chronic myelogenous (or myeloid) leukemia (CML)
- Colorectal cancer
- Endometrial
- Gastrointestinal stromal tumor (GIST)
- Gliomas
- Head and neck cancer
- Hepatocellular carcinoma
- Idiopathic thrombocytopenic purpura (ITP)
- Lymphoma
- Malignant ascites
- Melanoma
- Multiple myeloma
- Myelodysplastic syndrome (MDS)
- Neuroendocrine
- Lung cancer
- oGVHD
- Ovarian cancer
- Pancreatic cancer
- Pediatric cancers
- Prostate cancer
- Renal cell carcinoma
- Sarcoma
Connect with us.
Interested in receiving a proposal from Vial? Leave us a message and some of your contact info and we’ll be in touch with you shortly.
